BiotechTube

CT-P10 + Rituxan

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Follicular Lymphoma

Conditions

Follicular Lymphoma

Trial Timeline

Nov 9, 2015 → Sep 4, 2019

NCT ID
NCT02260804

About CT-P10 + Rituxan

CT-P10 + Rituxan is a phase 3 stage product being developed by Celltrion for Follicular Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02260804. Target conditions include Follicular Lymphoma.

What happened to similar drugs?

1 of 20 similar drugs in Follicular Lymphoma were approved

Approved (1) Terminated (5) Active (14)
✅Obinutuzumab + Bendamustine + Cyclophosphamide + Doxorubicin + Prednisone/Prednisolone/Methylprednisolone + VincristineRocheApproved
🔄DRL_RI (Proposed rituximab biosimilar)Dr. Reddy's LaboratoriesPhase 3
🔄Rituxan + CT-P10 + Cyclophosphamide + Vincristine + PrednisoneCelltrionPhase 3
❌Zandelisib + Rituximab + Bendamustine + CHOPKyowa KirinPhase 3
🔄Epcoritamab + Rituximab + LenalidomideAbbViePhase 3
🔄Epcoritamab + Prednisone + Rituximab + Lenalidomide + Doxorubicin + Vincristine + Cyclophosphamide + Obinutuzumab + BendamustineAbbViePhase 3
🔄Surovatamig + R-CHOP + R-CVP + BRAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02260804Phase 3Completed

Competing Products

20 competing products in Follicular Lymphoma

See all competitors
ProductCompanyStageHype Score
DRL_RI (Proposed rituximab biosimilar)Dr. Reddy's LaboratoriesPhase 3
37
EnzastaurinEli LillyPhase 2
35
Rituxan + CT-P10 + Cyclophosphamide + Vincristine + PrednisoneCelltrionPhase 3
40
TazemetostatEisaiPre-clinical
30
Zandelisib + Rituximab + Bendamustine + CHOPKyowa KirinPhase 3
32
Pirtobrutinib + MosunetuzumabEli LillyPhase 2
42
fludarabine + rituximab + VELCADEJohnson & JohnsonPhase 2
27
SHR2554Jiangsu Hengrui MedicinePhase 2
42
Epcoritamab + RituximabAbbViePhase 2
42
Epcoritamab + Rituximab + LenalidomideAbbViePhase 3
44
Ibrutinib + VenetoclaxAbbViePhase 1/2
32
Epcoritamab + Prednisone + Rituximab + Lenalidomide + Doxorubicin + Vincristine + Cyclophosphamide + Obinutuzumab + BendamustineAbbViePhase 3
47
Venetoclax + Bendamustine + RituximabAbbViePhase 2
35
Acalabrutinib + ObinutuzumabAstraZenecaPhase 2
42
Surovatamig + R-CHOP + R-CVP + BRAstraZenecaPhase 3
47
Gonal-F (Follitropin alfa)MerckPre-clinical
26
Eltrombopag and VorinostatMerckPhase 2
27
Recombinant-follicle stimulating hormone (r-FSH)MerckPre-clinical
18
Acalabrutinib + PembrolizumabMerckPhase 1/2
32
Rituximab + Autologous dendritic cells + GM-CSF + PembrolizumabMerckPhase 2
35